Inflectra (Infliximab) ( DrugBank: Infliximab )


1 disease
IDDisease name (Link within this page)Number of trials
95Autoimmune hepatitis1

95. Autoimmune hepatitis


Clinical trials : 52 Drugs : 68 - (DrugBank : 28) / Drug target genes : 19 - Drug target pathways : 112
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003311-19-DE
(EUCTR)
09/01/201818/09/2017Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MABPhase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MAB Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histology. Untreated, AIH progresses to liver fibrosis and cirrhosis with its complications. Historical placebo-controlled studies could show a mortality of around 70% in the placebo-treated group.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Inflectra (Infliximab)University Medical Centre Hamburg-EppendorfNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 2Germany